Xanthine Oxidase Inhibitors in Heart Failure: Where Do We Go From Here?
Despite its public health impact, there are relatively few classes of drugs in use for the treatment of heart failure (HF) and left ventricular dysfunction.1 HF pharmacology is based upon relatively few signal transduction pathways - most prominently the sympathetic nervous system and the renin angiotensin aldosterone system.1 As such the quest for additional therapeutic targets remains critically important, and in this regard oxidative stress/nitroso-redox imbalance is a potential target of long standing interest.2
- nitroso-redox balance
- heart failure
- uric acid
- xanthine oxidase inhibitors heart failure
- nitric oxide
- Received April 5, 2015.
- Revision received April 10, 2015.
- Accepted April 10, 2015.